Major depressive disorder (MDD) is a debilitating condition that affects more than 246 million people worldwide, yet scientists have struggled to identify consistent brain markers that could improve ...

Major depressive disorder (MDD) is a debilitating condition that affects more than 246 million people worldwide, yet ...

A team of researchers, through a collaborative study, now points to functional connectome uniqueness (an individual-level ...

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...

Although antidepressants are a mainstay of MDD treatment, they are plagued by poor efficacy, high rates of relapse, and intolerable side effects. 40,41 Second-generation antidepressants, including ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of interest in everyday activities, appetite changes, sleep disturbances and, in ...

FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire-- ABVC BioPharma, Inc. (ABVC) (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company ...

Researchers found that 8.3% of US adults had at least one major depressive episode. In adolescents, the rate was 20.1%, with 29.2% of female adolescents reporting a major depressive episode. Major ...

Patients with asthma and major depressive disorder had more negative beliefs about their asthma, worse treatment adherence ...

17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of ...